Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17215668 | 0.85 | MCL1 (0.62) | ALDH1A1KMT2AMEN1POLBLMNA | |
| SCHEMBL2570325 | 0.78 | ALDH1A1 (0.52) | ALDH1A1KMT2AMEN1POLBLMNA | |
| SCHEMBL6602500 | 0.78 | LMNA (0.53) | ALDH1A1KMT2AMEN1LMNAPKM | |
| SCHEMBL2476165 | 0.77 | ALDH1A1 (1.00) | ALDH1A1KMT2AMEN1POLBLMNA | |
| SCHEMBL4095224 | 0.77 | ALDH1A1 (0.46) | ALDH1A1KMT2AMEN1POLBLMNA | |
| SCHEMBL4101227 | 0.77 | ALDH1A1 (0.46) | ALDH1A1KMT2AMEN1POLBLMNA | |
| SCHEMBL8193080 | 0.77 | ALDH1A1 (0.46) | ALDH1A1KMT2AMEN1POLBLMNA | |
| SCHEMBL2511290 | 0.74 | LMNA (0.45) | ALDH1A1KMT2AMEN1LMNAPKM | |
| SCHEMBL17158265 | 0.74 | KMT2A (0.48) | ALDH1A1KMT2AMEN1LMNAPKM | |
| SCHEMBL17158194 | 0.73 | KMT2A (0.48) | ALDH1A1KMT2AMEN1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2940008-B1 | NOVEL BENZAZEPINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | SANWA KAGAKU KENKYUSHO CO (JP) | 2017-05-17 | — | — | EP | disclosed |
| US-9586905-B2 | Benzoazepine derivative and medical use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2017-03-07 | — | — | US | disclosed |
| EP-2940008-A1 | NOVEL BENZAZEPINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Sanwa Kagaku Kenkyusho Co., Ltd (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-20150291533-A1 | NOVEL BENZOAZEPINE DERIVATIVE AND MEDICAL USE THEREOF | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291533-A1 | NOVEL BENZOAZEPINE DERIVATIVE AND MEDICAL USE THEREOF | AVPR2, AVPR1A, AVPR1B | ALDH1A1 1975/4885KMT2A 993/4885MEN1 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.